1~4 item / All 4 items
Displayed results
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registrationContact this company
Contact Us OnlineBefore making an inquiry
Download PDF1~4 item / All 4 items
The TC-huMDR1TM mouse is a trans-chromosomic (Tc: chromosomal insertion) mouse (B6 strain) that introduces the human MDR1 gene into a mouse that has knocked out the intrinsic mdr1a/1b genes (mMDR1-KOTM) using an "artificial chromosome vector," making it the world's first 'human-type P-gp model mouse' that expresses functional P-glycoprotein (P-gp). Features and Benefits: * Functional human P-gp protein is expressed. * The AUC of TC-huMDR1TM mice and mMDR1-KOTM mice can be used to evaluate human brain permeability and P-gp-mediated drug-drug interactions. * Using TC-huMDR1TM mice and physiological pharmacokinetic (PBPK) modeling, quantitative predictions of human nonlinear absorption mediated by P-gp can be made. * This allows for the selection of compounds with ideal pharmacokinetic profiles in drug discovery, facilitating more appropriate management of P-gp-mediated drug-drug interactions in clinical settings. *For more details, please refer to the PDF materials or feel free to contact us.*
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registrationAntibodies recognize foreign substances from the outside, activating the immune system and producing B cells. If you want to create human antibodies against a specific protein, due to ethical issues, it is not possible to administer the protein to humans to obtain antibody-producing cells. Traditionally, to produce antibodies against humans, the target protein was administered to animals like mice, whose immune systems would respond, allowing for the collection of antibody-producing cells. Then, the antigen recognition site would be analyzed, and the human antibody region would be substituted in a process called "humanization." When constructing human antibody-producing cells, the human antibody-producing gene is introduced into rat cells via a plasmid. The plasmid integrates into the host's chromosomes, which poses a problem as it can disrupt the function of other genes. Our company has successfully introduced a large human antibody-producing artificial chromosome vector into rat cells using chromosome engineering technology, allowing it to be stably maintained independently. 【Features】 ■ Rapid acquisition of human antibody-producing cells is possible ■ Increased potential to obtain antibody drug candidates *For more details, please refer to the catalog or feel free to contact us.
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registrationWe have created human-like drug metabolism model mice and rats equipped with artificial chromosome vectors carrying human drug metabolism-related genes. By administering new drugs, we can predict safety for humans, leading to accelerated pharmaceutical development and reduced costs. 【Features】 ■ Improved prediction of safety for humans ■ Accelerated pharmaceutical development and increased success rates ■ Lower costs for new drug development and reduced national healthcare burden *For more details, please refer to the catalog or feel free to contact us.
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registrationTransChromosomics Co., Ltd. is a bio-venture originating from Tottori University, established with the aim of developing drug discovery and drug discovery support tools, based on the know-how of chromosome engineering technology acquired by CEO Mitsuo Oshimura during his 30 years of research. Using cutting-edge chromosome engineering technology, we conduct chromosome modifications, iPS/ES cell production, genetically modified mouse and rat production, animal testing, antibody production, and more. 【Business Activities】 ■ Development of fully human antibody-producing rats ■ Development of genetic rare disease model animals and cell transplantation therapy ■ Development of human-like drug metabolism model animals ■ Contract testing For contract testing inquiries or questions, please use the contact form. You can also reach us through our official website. http://trans-chromo.wix.com/trans-chromosomics *For more details, please refer to our catalog or feel free to contact us.
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registration